Progression to AIDS in south africa is associated with both reverting and compensatory viral mutations

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Huang, Kuan Hsiang Gary ^a,n   Goedhals, Dominique ^b,c   Carlson, Jonathan M ^d   Brockman, Mark A ^e,f,g   Mishra, Swati ^a   Brumme, Zabrina L ^e,f,g   Hickling, Stephen ^a   Tang, Christopher S W ^a   Miura, Toshiyuki ^g,h   Seebregts, Chris ⁱ   Heckerman, David ^d   Ndung'u, Thumbi ^j   Walker, Bruce ^j,k,l   Klenerman, Paul ^a,o   Steyn, Dewald ^b   Goulder, Philip ^m   Phillips, Rodney ^a,n,o   van Vuuren, Cloete ^b   Frater, John ^a,o  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d MICROSOFT RESEARCH   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

^f BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^j UNIVERSITY OF KWAZULU NATAL   (South Africa)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l HARVARD UNIVERSITY   (United States)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ UNIVERSITY OF OXFORD   (United Kingdom)

^o NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; GAG PROTEIN; NEF PROTEIN; POL PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; GENE; GENE FREQUENCY; GROUP SPECIFIC ANTIGEN GENE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NEF GENE; NONHUMAN; SOUTH AFRICA; STRUCTURAL GENE; T LYMPHOCYTE; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC POLYMORPHISM; GENETICS; MUTATION; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSPOT ASSAY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MUTATION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, GENETIC; SOUTH AFRICA;

EID: 79955533328     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019018     Document Type: Article

References (41)

1. Herbeck JT, Gottlieb GS, Winkler CA, Nelson GW, An P, et al. Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS. J Infect Dis 201: 618-626.
2. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944-947.
3. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, et al. (2009) Common genetic variation and the control of HIV-1 in humans. PLoS Genet 5: e1000791.
4. Carrington M, O'Brien SJ, (2003) The influence of HLA genotype on AIDS. Annu Rev Med 54: 535-551.
5. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, et al. (2005) AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 11: 1290-1292.
6. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B In mediating the potential co-evolution of HIV and HLA. Nature 432: 769-774.
7. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, et al. (2010) Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465: 350-354.
8. Shafer RW, Rhee SY, Bennett DE, (2008) Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther 13 (Suppl 2): 59-68.
9. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, et al. (2007) HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids 21: 215-223.
10. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, et al. (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354: 453-459.
11. Goulder PJ, Watkins DI, (2004) HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4: 630-640.
12. Brumme ZL, Tao I, Szeto S, Brumme CJ, Carlson JM, et al. (2008) Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. Aids 22: 1277-1286.
13. Brumme ZL, Brumme CJ, Heckerman D, Korber BT, Daniels M, et al. (2007) Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 3: e94.
14. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, et al. (2007) Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315: 1583-1586.
15. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, et al. (2004) Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol 78: 8927-8930.
16. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. (2009) Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458: 641-645.
17. Frater AJ, Brown H, Oxenius A, Gunthard HF, Hirschel B, et al. (2007) Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol 81: 6742-6751.
18. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, et al. (2006) Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 80: 3617-3623.
19. Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, et al. (2009) HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 83: 140-149.
20. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, et al. (2008) Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 205: 1009-1017.
21. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, et al. (2007) Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 81: 12382-12393.
22. Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, et al. (2009) HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol 83: 1228-1239.
23. Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M, et al. (2008) Marked epitope and allele-specific differences in rates of mutation in HIV-1 Gag, Pol and Nef CTL epitopes in acute/early HIV-1 infection. J Virol.
24. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, et al. (2007) Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2: e321.
25. Zhuang Y, Sun Y, Zhai S, Huang D, Zhao S, et al. (2008) Relative dominance of Env-gp41-specific cytotoxic T lymphocytes responses in HIV-1 advanced infection. Curr HIV Res 6: 239-245.
26. Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, et al. (2003) Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 37: 1693-1698.
27. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, et al. (2007) Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol 81: 12608-12618.
28. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, et al. (2001) Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 193: 375-386.
29. Huang KH, Goedhals D, Fryer H, van Vuuren C, Katzourakis A, et al. (2009) Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa. Antivir Ther 14: 975-984.
30. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77: 2081-2092.
31. Carlson JM, Brumme ZL, Rousseau CM, Brumme CJ, Matthews P, et al. (2008) Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol 4: e1000225.
32. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, et al. (2010) Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters. J Virol.
33. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, et al. (2010) Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated in chronic infection. J Virol.
34. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, et al. (2010) Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 84: 7581-7591.
35. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, et al. (2008) Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol 82: 8548-8559.
36. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282-289.
37. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, et al. (2009) Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 83: 7641-7648.
38. Services DoHaH (2009) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. pp. 1-161 Department of Health and Human Services. http://wwwaidsinfonihgov/ContentFiles/AdultandAdolescentGLpdf.
39. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, et al. (2008) HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol 82: 6434-6446.
40. Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, et al. (2010) Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol 84: 4461-4468.
41. Walker S, DART Trial Team Design of the DART trial and key substudy results; 2009; Cape Town, South Africa.